International Stem Cell Corporation Announces Successful

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
International Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC

CARLSBAD, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that the first patient in the previously announced Phase I clinical trial has undergone a successful intracranial transplant of ISC-hpNSC as a treatment under investigation for Parkinson’s Disease (PD). The operation took place at The Royal Melbourne Hospital in Australia.

The phase I clinical trial will evaluate the safety and tolerability of ISCO’s human parthenogenetic stem cell therapy, which uses cells that are cGMP and ethically manufactured through the company’s proprietary technology.

Andrey Semechkin, PhD, ISCO’s Co-Chairman and CEO, said, "We believe that stem cells are part of the solution to finding a cure for Parkinson’s Disease.  There is real potential for millions of people who currently suffer from Parkinson's Disease to truly benefit from using ISC-hpNSC.”

Russell Kern, PhD, executive vice president and chief scientific officer of ISCO, commented, “This is a major step forward in our search for a cure for Parkinson’s Disease.  We are thrilled to initiate this clinical trial and prove that neural stem cells can be a part of the solution. We are hopeful that ISC-hpNSC will prove to be a valuable therapy. The operation which took place at The Royal Melbourne Hospital to transplant neural stem cells into the patient’s brain went according to plan.”

About the clinical study

The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC ® , intracranially transplanted into patients with moderate to severe Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals, to evaluate the safety and biologic activity of ISC-hpNSC ® . PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC ®  will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales.

The study is underway at The Royal Melbourne Hospital in Australia. The study is being overseen by ISCO subsidiary, Cyto Therapeutics Pty Ltd.

About Parkinson's disease

Parkinson's disease (PD) is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related; these symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression is the most common psychiatric symptom. Parkinson's disease is more common in older people, with most cases occurring after the age of 50.

Currently, medications typically used in the treatment of Parkinson's, L-DOPA and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective while at the same time frequently producing a complication marked by involuntary writhing movements. In 2013 PD resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.

About ISC-hpNSC   ®

International Stem Cell Corporation's proprietary ISC-hpNSC ®  consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC ®  is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC ® . ISC-hpNSC ®  provides neurotrophic support and cell replacement to the dying dopaminergic neurons of the recipient PD brain. Additionally, ISC-hpNSC ®  are safe, well tolerated and do not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC ®  may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.

About International Stem Cell Corporation

International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ( www.lifelinecelltech.com ), and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( www.lifelineskincare.com ). More information is available at  www.internationalstemcell.com .

To subscribe to receive ongoing corporate communications, please click on the following link:  http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit:  www.facebook.com/InternationalStemCellCorporation  and  www.twitter.com/intlstemcell

Safe harbor statement

Statements pertaining to anticipated developments, expected results and timing of clinical studies, potential applications of ISC-hpNSC ®  to other diseases, progress of research and development initiatives, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Contacts:

International Stem Cell Corporation Russell A. Kern, PhD Phone: 760-940-6383 Email: ir@intlstemcell.com

Alex Fudukidis Russo Partners Tel.: +1 646 942 5632 E-mail: alex.fudukidis@russopartnersllc.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 454

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 387

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 162

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 66

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 77

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 304

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Ventas to Showcase Investment Strategy at Real Estate Conference

Updated Category News Views 44

Ventas Engages Investors at Upcoming Conference Ventas, Inc. (NYSE: VTR) is gearing up to take part in significant investor meetings at the BofA Securities 2024 Global Real Estate Conference. This event presents a valuable chance for the company to connect with investors and share insights about its strategic direction and business model. Event Details and Participation...

Continue Reading
BioLineRx Explores Synergy in Ovarian Cancer Treatment

Updated Category News Views 151

New Hope on the Ovarian Cancer Front Every so often, something comes along and makes you stop and think—could this be the game-changer in the making? Well, what BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS just dropped at the ESMO 2026 feels a bit like that silver lining for folks fighting the uphill battle against homologous recombination (HR)-proficient ovarian...

Continue Reading
Analyst Ratings Show Confidence in Datadog and Others

Updated Category News Views 80

Recent Upgrades by Top Analysts Leading financial analysts from Wall Street have adjusted their outlooks on several prominent companies, reflecting a more optimistic market sentiment. Upgrades often signify increased confidence in a company's performance and present potential investment opportunities for savvy investors. Here, we delve into some of the standout upgrades...

Continue Reading
Unpacking the Increased Short Interest in Ventas (NYSE: VTR)

Updated Category News Views 77

Understanding Ventas's Short Interest Surge Ventas recently recorded an uptick in its short percent of float, which now stands at 25.59% since the last report. This notable development means that 9.80 million shares are currently sold short, translating to 3.19% of all regular shares available for trading. Given the trading volume, it would take traders approximately 3.33...

Continue Reading
Precigen's PAPZIMEOS: 7-Year Exclusivity & Long-Term Success

Updated Category News Views 54

Precigen's Game-Changer: PAPZIMEOS Secures Seven-Year Exclusivity Here's how you carve out a solid niche in the biotech world: deliver some killer results and snag yourself seven years in the driver’s seat. That's exactly what Precigen (NASDAQ: PGEN) has done with their PAPZIMEOS therapy, which got the stamp of approval from the FDA as the first exclusive treatment for...

Continue Reading